Argus Boosts Rating On Bioverativ Inc. (BIVV) To “Buy”


Bioverativ Inc. (NASDAQ:BIVV).

Equity analyst RBC Capital added the stock to its research portfolio by announcing an initial rating of “Sector Perform”. Evercore ISI Group initiated coverage on the stock with an initial rating of “In-Line”.

On June 28 analysts at William Blair starting coverage on BIVV with a rating of “Hold”. On June 23, 2017 Deutsche Bank began coverage of the stock giving it an initial rating of “Hold”.

The company is now up since yesterday’s close of 56.39. It is trading at $56.79 which is just over the 50 day moving average of $56.33 and barely above the 200 day moving average of $56.33. The 50 day moving average went up $0.46 or +0.81% and the 200 day average moved up $0.46.

Bioverativ Inc.’s P/E ratio is 13.50 and the market value is 6.14B. As of the latest earnings report the EPS was $4.21 and is expected to be $2.89 for the current year with 108,182,000 shares outstanding. Analysts expect next quarter’s EPS to be $0.68 and the next full year EPS is projected to be $3.21.

Investors are more bearish on shares of Bioverativ Inc. lately if you look at the uptick in short interest. The company realized a rise in short interest from August 15, 2017 to August 31, 2017 of 20.68%. Short shares increased from 4,380,074 to 5,285,751 over that timeframe. The short-interest ratio increased to 6.0 and the short interest percentage is 0.05% as of August 31.